Carmelita Carrier
New York Blood Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carmelita Carrier.
The New England Journal of Medicine | 1998
Pablo Rubinstein; Carmelita Carrier; Andromachi Scaradavou; Joanne Kurtzberg; John W. Adamson; Anna Rita Migliaccio; Richard L. Berkowitz; Michael F. Cabbad; Dobrila Nl; Patricia E. Taylor; Richard E. Rosenfield; Cladd E. Stevens
BACKGROUND A program for banking, characterizing, and distributing placental blood, also called umbilical-cord blood, for transplantation provided grafts for 562 patients between August 24, 1992, and January 30, 1998. We evaluated this experience. METHODS Placental blood was stored under liquid nitrogen and selected for specific patients on the basis of HLA type and leukocyte content. Patients were prepared for the transplantation of allogeneic hematopoietic cells in the placental blood and received prophylaxis against graft-versus-host disease (GVHD) according to routine procedures at each center. RESULTS Outcomes at 100 days after transplantation were known for all 562 patients, and outcomes at 1 year for 94 percent of eligible recipients. The cumulative rates of engraftment among the recipients, according to actuarial analysis, were 81 percent by day 42 for neutrophils (median time to engraftment, 28 days) and 85 percent by day 180 for platelets (median, day 90). The speed of myeloid engraftment was associated primarily with the leukocyte content of the graft, whereas transplantation-related events were associated with the patients underlying disease and age, the number of leukocytes in the graft, the degree of HLA disparity, and the transplantation center. After engraftment, age, HLA disparity, and center were the primary predictors of outcome. Severe acute GVHD (grade III or IV) occurred in 23 percent of patients, and chronic GVHD occurred in 25 percent. The rate of relapse among recipients with leukemia was 9 percent within the first 100 days, 17 percent within 6 months, and 26 percent by 1 year. These rates were associated with the severity of GVHD, type of leukemia, and stage of the disease. CONCLUSIONS Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution.
The New England Journal of Medicine | 1996
Joanne Kurtzberg; Mary J. Laughlin; Michael L. Graham; Clay Smith; Olson J; Edward C. Halperin; G. Ciocci; Carmelita Carrier; Cladd E. Stevens; Pablo Rubinstein
BACKGROUND Transplantation of bone marrow from unrelated donors is limited by a lack of HLA-matched donors and the risk of graft-versus-host disease (GVHD). Placental blood from sibling donors can reconstitute hematopoiesis. We report preliminary results of transplantation using partially HLA-mismatched placental blood from unrelated donors. METHODS Twenty-five consecutive patients, primarily children, with a variety of malignant and non-malignant conditions received placental blood from unrelated donors and were evaluated for hematologic and immunologic reconstitution and GVHD. HLA matching was performed before transplantation by serologic typing for class I HLA antigens and low-resolution molecular typing for class II HLA alleles. In donor-recipient pairs who differed by no more than one HLA antigen or allele, high-resolution class II HLA typing was done retrospectively. Fordonor-recipient pairs who were mismatched for two HLA antigens or alleles, high-resolution typing was used prospectively to select the best match for HLA-DRB1. RESULTS Twenty-four of the 25 donor-recipient pairs were discordant for one to three HLA antigens. In 23 of the 25 transplant recipients, the infused hematopoletic stem cells engrafted. Acute grade III GVHD occurred in 2 of the 21 patients who could be evaluated, and 2 patients had chronic GVHD. In vitro proliferative responses of T cells and B cells to plant mitogens were detected 60 days after transplantation. With a median follow-up of 12 1/2 months and a minimal follow-up of 100 days, the overall 100-day survival rate among these patients was 64 percent, and the overall event-free survival was 48 percent. CONCLUSIONS HLA-mismatched placental blood from unrelated donors is an alternative source of stem cells for hematopoietic reconstitution in children.
Proceedings of the National Academy of Sciences of the United States of America | 2009
Jon J. van Rood; Cladd E. Stevens; Jacqueline M. Smits; Carmelita Carrier; Carol Carpenter; Andromachi Scaradavou
Cord blood (CB) hematopoietic stem cell transplantation can be successful even if donor and recipient are not fully matched for human leukocyte antigens (HLA). This may result from tolerance-inducing events during pregnancy but to date this concept has not been tested in CB transplantation. Hence we analyzed the impact of fetal exposure to noninherited maternal antigens (NIMA) of the HLA-A, -B antigens, or -DRB1 alleles on the outcome of CB transplants. The 1,121 patients studied were transplanted for hematological malignancy with a single CB unit: 1,059 received grafts mismatched for one or two HLA antigens. Of these patients, 79 patients had a mismatched antigen that was identical to a donor NIMA, 25 with one HLA mismatch (MM), and 54 with two. If there was a NIMA match, transplant-related mortality (TRM) was improved, especially in patients ≥10 years (P = 0.012) as were overall mortality and treatment failure (P = 0.022 and 0.020, respectively, in the older subset), perhaps related to improved neutrophil recovery, especially in patients who received a low total nucleated cell (TNC) dose (P = 0.031). Posttransplant relapse rate also tended to be reduced, especially in patients with myelogenous malignancies given units with a single HLA mismatch (P = 0.074). These findings represent unique evidence that donor exposure to NIMA can improve survival in unrelated CB transplantation and might reduce relapse, indicating that cord blood cells can mount an antileukemic effect. By matching for donor NIMAs in search algorithms of CB inventories, the probability of selecting a graft with an optimal outcome will increase significantly.
Blood | 2000
Anna Rita Migliaccio; John W. Adamson; Cladd E. Stevens; N. Ludy Dobrila; Carmelita Carrier; Pablo Rubinstein
Blood | 1996
Andromachi Scaradavou; Carmelita Carrier; Norman Mollen; Cladd E. Stevens; Pablo Rubinstein
Blood | 2011
Cladd E. Stevens; Carmelita Carrier; Carol Carpenter; Dorothy Sung; Andromachi Scaradavou
Blood | 2002
Cladd E. Stevens; Jessica R. Gladstone; Patricia E. Taylor; Andromachi Scaradavou; Anna Rita Migliaccio; Jan Visser; N. Ludy Dobrila; Carmelita Carrier; Michael F. Cabbad; Peter Wernet; Joanne Kurtzberg; Pablo Rubinstein
Blood | 2006
Maria S. Albano; Patricia A. Taylor; Robert F. Pass; Andromachi Scaradavou; Rodica Ciubotariu; Carmelita Carrier; Ludy Dobrila; Pablo Rubinstein; Cladd E. Stevens
Human Immunology | 1989
Carmelita Carrier; N. Mollen; W.C. Rothman; S. Rodriguez de Cordoba; J. Rey-Campos; Fredda Ginsberg-Fellner; C. Carpenter; Pablo Rubinstein
Blood | 2005
Cladd E. Stevens; Andromachi Scaradavou; Carmelita Carrier; Carol Carpenter; Pablo Rubinstein